[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654814":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":16,"studyPopulation":16,"armGroups":23,"interventions":29,"overallOfficials":33,"centralContacts":37,"locations":43,"responsibleParty":146,"collaborators":16,"id":148,"slug":149,"hasResults":150,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":150,"sex":156,"minAge":157,"maxAge":16,"enrollmentInfo":158,"targetDuration":16,"studyType":161,"phases":162,"briefSummary":153,"conditions":165,"keywords":16,"overallStatus":46,"whyStopped":16,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":176},{"fullName":5,"class":6},"Orion Corporation, Orion Pharma","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":16},[9,13],{"measure":10,"description":11,"timeFrame":12},"Incidence of dose-limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), treatment-related adverse events, and clinical laboratory abnormalities (including electrocardiogram [ECG]).","To evaluate the safety and tolerability of ODM-216 to determine the maximum tolerated dose (MTD) if applicable or maximum feasible dose (MFD) if applicable.","12 months",{"measure":10,"description":14,"timeFrame":15},"To identify one or two recommended Part 2 doses (RP2Ds) for subsequent confirmation as the optimal biological dose (OBD) in Part 2.","22 months",null,{"allocation":18,"interventionModel":19,"interventionModelDescription":16,"primaryPurpose":20,"observationalModel":16,"timePerspective":16,"maskingInfo":21},"NA","SEQUENTIAL","TREATMENT",{"masking":22,"maskingDescription":16,"whoMasked":16},"NONE",[24],{"label":25,"type":26,"description":25,"interventionNames":27},"ODM-216","EXPERIMENTAL",[28],"Drug: ODM-216",[30],{"type":31,"name":25,"description":25,"armGroupLabels":32,"otherNames":16},"DRUG",[25],[34],{"name":35,"affiliation":5,"role":36},"Study Director Clinical Study Director","STUDY_DIRECTOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":16,"email":42},"Clinical Study Director Clinical Study Director","CONTACT","+358104261","clinicaltrials@orionpharma.com",[44,65,81,96,107,119,132],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"START Rioja - Hospital Universitario San Pedro","RECRUITING","Logroño","La Rioja","26006","Spain","ES",{"type":53,"coordinates":54},"Point",[55,56],-2.45115,42.46615,{"lat":56,"lon":55},[59,63],{"name":60,"role":40,"phone":61,"phoneExt":16,"email":62},"Maria Demiguel","+34941278760","maria.demiguel@startrioja.com",{"name":60,"role":64,"phone":16,"phoneExt":16,"email":16},"PRINCIPAL_INVESTIGATOR",{"facility":66,"status":46,"city":67,"state":68,"zip":69,"country":50,"countryCode":51,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"NEXT Oncology - Hospital Quironsalud Madrid","Madrid","Pozuelo de Alarcón - Madrid","28223",{"type":53,"coordinates":71},[72,73],-3.70256,40.4165,{"lat":73,"lon":72},[76,80],{"name":77,"role":40,"phone":78,"phoneExt":16,"email":79},"Valentina Boni","+34914521900","vboni@nextoncology.eu",{"name":77,"role":64,"phone":16,"phoneExt":16,"email":16},{"facility":82,"status":46,"city":83,"state":16,"zip":84,"country":50,"countryCode":51,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"START Barcelona - HM Nou Delfos","Barcelona","08023",{"type":53,"coordinates":86},[87,88],2.15899,41.38879,{"lat":88,"lon":87},[91,95],{"name":92,"role":40,"phone":93,"phoneExt":16,"email":94},"Tatiana Hernandez","+34932545030","tatiana.hernandez@start-barcelona.com",{"name":92,"role":64,"phone":16,"phoneExt":16,"email":16},{"facility":97,"status":46,"city":67,"state":16,"zip":98,"country":50,"countryCode":51,"cosmosGeoPoint":99,"geoPoint":101,"contacts":102},"Clinica Universidad de Navarra - Madrid","28027",{"type":53,"coordinates":100},[72,73],{"lat":73,"lon":72},[103],{"name":104,"role":40,"phone":105,"phoneExt":16,"email":106},"Ignacio Ortego Zabalza","+34 948 255 400","iortegoz@unav.es",{"facility":108,"status":46,"city":67,"state":16,"zip":109,"country":50,"countryCode":51,"cosmosGeoPoint":110,"geoPoint":112,"contacts":113},"Hospital Universitario Fundacion Jimenez Diaz - START MADRID","28040",{"type":53,"coordinates":111},[72,73],{"lat":73,"lon":72},[114,118],{"name":115,"role":40,"phone":116,"phoneExt":16,"email":117},"Manuel Pedregal","+34915504800","manuel.pedregal@startmadrid.com",{"name":115,"role":64,"phone":16,"phoneExt":16,"email":16},{"facility":120,"status":46,"city":67,"state":16,"zip":121,"country":50,"countryCode":51,"cosmosGeoPoint":122,"geoPoint":124,"contacts":125},"START Madrid - CIOCC FM Sanchinarro","28050",{"type":53,"coordinates":123},[72,73],{"lat":73,"lon":72},[126,130],{"name":127,"role":40,"phone":128,"phoneExt":16,"email":129},"Irene Moreno Principal Investigator","+34 917567825","Irene.moreno@startmadrid.com",{"name":131,"role":64,"phone":16,"phoneExt":16,"email":16},"Irene Moreno",{"facility":133,"status":46,"city":134,"state":16,"zip":135,"country":50,"countryCode":51,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"Clínica Universidad de Navarra. Pamplona","Pamplona","31008",{"type":53,"coordinates":137},[138,139],-1.64323,42.81687,{"lat":139,"lon":138},[142,145],{"name":143,"role":40,"phone":144,"phoneExt":16,"email":106},"Ignacio Ortego","+34948255400",{"name":143,"role":64,"phone":16,"phoneExt":16,"email":16},{"type":147,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR","100654814","phase-1-trial-to-study-the-safety-pharmacokinetics-and-preliminary-antitumour-activity-of-odm-216-in-patients-with-cancer-100654814",false,"NCT07805252","Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer","A Phase 1\u002F2, Open-Label, First-in-Human Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumour Activity of ODM-216 in Participants With Advanced Solid Tumours","BICIDES","Key Eligibility Requirements.\n\nA participant must:\n\n1. Understand the trial procedures and agree to participate by giving written, signed, and dated informed consent (IC; or witness consent).\n2. Male or female participants ≥18 years old.\n3. Have a performance status of 0 or 1 on the ECOG performance scale.\n4. Participants must be willing and able to undergo a baseline tumour biopsy; for further information please refer to protocol.\n\n6\\. Participants must have a histologically or cytologically confirmed advanced solid malignancy and be refractory to or intolerant to established standard of care therapies known to provide clinical benefit as determined by the investigator.\n\n7\\. Participants must have measurable disease per RECIST v1.1, including at least one lesion that is measurable and appropriate for response evaluation. Lesions within a previously irradiated field are permissible as measurable disease provided that clear radiologic progression has been demonstrated and accurate measurement is feasible.\n\n8\\. Refer to the protocol for the full list of inclusion criteria\n\nExclusion Criteria\n\n1. Received prior chemotherapy, targeted therapy, or treatment with an investigational anticancer agent within 21 days; or immunotherapy or definitive\u002Fcurative intent radiation therapy within 28 days, before receiving their first dose of ODM-216.\n2. Have an autoimmune disease that has required systemic treatment in the past 2 years (i.e. use of disease modifying agents, high dose corticosteroids, or immunosuppressive drugs).\n3. Brain metastases unless asymptomatic and not requiring steroids for at least 2 weeks prior to the first dose of trial treatment. These should be previously treated and shown to be stable for at least 3 months post treatment.\n4. Refer to the protocol for the full list of exclusion criteria","ALL","18 Years",{"count":159,"type":160},195,"ESTIMATED","INTERVENTIONAL",[163,164],"PHASE1","PHASE2",[166],"Advanced Solid Tumors Cancer","2026-09-21",{"date":169,"type":170},"2026-09-24","ACTUAL",{"date":172,"type":170},"2026-09-03",{"date":174,"type":160},"2028-01-10",{"name":5,"class":6},7]